Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
FAQs on Developing EMA Policy 0070 Submissions
This blog answers audience questions posed during our RAPS webinar, How to Plan for a…
CertaraSeptember 15, 2025
The Top 10 Things You Need to Know About ADNCA Datasets
Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…
CertaraSeptember 11, 2025
Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research
The article, "Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research," explores a…
Danielle PillsburySeptember 10, 2025
AI-driven drug discovery picks up as FDA pushes to reduce animal testing
AI is revolutionizing drug discovery and safety testing as drug developers adopt these technologies in…
CertaraSeptember 9, 2025
Large Biotech Streamlines Investigator’s Brochures with Certara’s Project Management Expertise
Learn how Certara's project management team helped a large biotech streamline the development and updates…
CertaraSeptember 5, 2025
